Skip to main content

Thomas Alexander, MD, MPH, is a UNC Lineberger Comprehensive Cancer Center member combining cancer genomic sequencing with early phase clinical trials to enhance understanding of disease response dynamics and improve outcomes in childhood leukemia and other hematological malignancies.

MD, MPH
Assistant Professor, Pediatrics
UNC-Chapel Hill
Clinical Research

Meet Thomas Alexander

Area of Interest

Thomas Alexander, MD, MPH, is combining cancer genomic sequencing with global health research collaborators to increase access to accurate and accessible, diagnostic testing for children with cancer.

His priority area of translational research is the development of resource-appropriate diagnostic techniques for pediatric cancer in low- and middle-income countries (LMIC). Over 80% of children who develop cancer worldwide are diagnosed in LMIC, where access to diagnostic technologies is limited and survival rates are low. To address this health disparity, he is advancing an innovative, cost-effective sequencing approach to expand global access to comprehensive pediatric cancer diagnostics. Dr. Alexander and his collaborators began with a focus on leukemia but have expanded their focus to include pediatric solid tumors. The components of the research include technical and computational development using a Nanopore sequencing approach, and implementation science approach through international collaborations. The research involves close collaborations with researchers in the Department of Biology, Department of Genetics, and the School of Pharmacy at UNC. Through this research, he collaborates closely with researchers at St. Jude Children’s Research Hospital as well as teams in Malawi, Pakistan, Uganda, Brazil, and India.

Additionally, he participates in clinical trial development and leadership through multiple pediatric oncology networks, including national cooperative groups, institutional collaborations, and industry-sponsored studies, primarily focused on clinical trials to advance therapy for children with acute leukemia. In 2023, he became the site principal investigator for the Children’s Oncology Group (COG), where he leads between 15-25 active trials at UNC open through the COG.

Find publications on PubMed

Awards and Honors

  • R21 NIH Grant, Principle Investigator, 2022-2024
  • Clinical Trialist Training Program Scholar, 2022-2023
  • UNC K12 Oncology Grant Aware, 2021-2023
  • Carolina For The Kids Faculty Investigator Award, 2020-2021
  • St. Baldrick Research Award Grant, 2019-2020
  • Abstract Achievement Award, American Society of Hematology, 2016
  • Young Investigator Travel Grant, Society for Hematologic Oncology, 2015
  • WakeMed Pediatric Resident of the Year, 2012-2013
  • Harvey J. Hamrick Award for Excellence in Teaching, UNC Pediatrics, 2012-2013
  • Floyd W. Denny Alumni Society Resident Award, UNC Pediatrics, 2012-2013
  • Harvey J. Hamrick Award for Excellence in Teaching, UNC Pediatrics, 2010-2011

News and Stories


View all related posts